Embark Early Education Ltd

Inverna Therapeutics, leveraging Professor Brage Storstein Andresen's RNA splicing research, focuses on sequence-based splice modulation for precise, allele-specific treatments targeting pseudoexons to correct splicing errors. Supported by Argobio, it aims to treat diseases like Huntington's with minimal off-target effects.

The global Oncology Based In-Vivo CRO market, valued at US$1.5 Billion in 2023, is projected to grow to US$2.5 Billion by 2030, driven by the increasing prevalence of cancer and advancements in preclinical research tools. Services include pharmacokinetics, pharmacodynamics, toxicology, and efficacy testing, with significant demand in lung and breast cancer studies. The market's growth is further supported by collaborations between CROs and biopharma companies, and the rise in innovative oncology therapies.

2024 was a challenging year for the biopharma industry, with companies like Bayer, Bristol Myers Squibb, and Johnson & Johnson cutting hundreds to thousands of jobs. Cassava Sciences announced layoffs of 10 employees, 33% of its workforce, following a failed Phase III trial for its Alzheimer's drug. CytomX Therapeutics cut 40% of its staff to focus on clinical programs. Velia, a San Diego biotech, is shutting down, affecting 47 employees. Regeneron's acquisition of Oxular led to layoffs, with no Oxular employees joining Regeneron. Javara, Ring Therapeutics, Outlook Therapeutics, Editas, Bavarian Nordic, BenevolentAI, Chroma Medicine and Nvelop Therapeutics, Cellectar Biosciences, Carisma Therapeutics, Belharra Therapeutics, National Resilience, AmplifyBio, Agenus, Alligator Bioscience, Idorsia Pharmaceuticals, Kronos Bio, Novartis, Recursion Therapeutics, Medigene, Alector, Bristol Myers Squibb, Sonata Therapeutics, 23andMe, Johnson & Johnson, Merck, Gilead Sciences, Adaptimmune, Sensei Biotherapeutics, Marinus Pharmaceuticals, Orna Therapeutics, Thermo Fisher Scientific, Charles River Laboratories, Aurinia Pharmaceuticals, Viracta Therapeutics, Astellas Gene Therapies, Sana Biotechnology, Sage Therapeutics, Compass Pathways, Spero Therapeutics, ICON, Pfizer, Takeda, SalioGen Therapeutics, Evonik, Medtronic, CareFusion Resources, Turnstone Biologics, Leo Pharma, Astellas Pharma, Prime Medicine, Kaléo, Stryker, Relay Therapeutics, ImmunityBio, Shattuck Labs, Inventprise, bluebird bio, Athira Pharma, AGC Biologics, Oncternal Therapeutics, Biosense Webster, Vesigen Therapeutics, Connect Biopharma, BioMarin, IN8bio, Edwards Lifesciences, DermTech, Repare Therapeutics, Genentech, Tome Biosciences, Aadi Bioscience, Lykos Therapeutics, Evotec, Galera Therapeutics, Grail, Ovid Therapeutics, Lexicon Pharmaceuticals, Acelyrin, Boundless Bio, FibroGen, Ajinomoto Bio-Pharma Services, AN2 Therapeutics, Entero Therapeutics, Precigen, Sumitomo Pharma America, uniQure, Vir Biotechnology, Arbutus Biopharma, HilleVax, and Bayer also announced significant layoffs, reflecting a tough year for the industry.

QUANTRO Therapeutics completed a 10-target multiplex-screening campaign, advancing drug discovery for cancer and inflammation. CEO Dr. Michael Bauer will attend Biotech Showcase and WuXi Global Forum in San Francisco to discuss QUANTRO's innovative QUANTROseq® platform, which enables precise transcription factor targeting.

Recursion Pharmaceuticals advances clinical trials for cancer drugs REC-3565 and REC-4539, targeting B-cell malignancies and small-cell lung cancer, respectively. With strong financials and AI-driven drug discovery, the company aims to develop first- and best-in-class oncology treatments, supported by regulatory approvals and positive preclinical results.

QUANTRO Therapeutics completed a 10-target multiplex-screening campaign, advancing its QUANTROseq® platform for cancer and inflammation treatments. CEO Dr. Michael Bauer will attend Biotech Showcase and WuXi Global Forum 2025 to discuss transcriptomic drug discovery and seek partnerships.

QUANTRO Therapeutics completed a 10-target multiplex-screening campaign, advancing its QUANTROseq® platform for cancer and inflammation treatments. CEO Dr. Michael Bauer will attend Biotech Showcase and WuXi Global Forum in San Francisco, January 13-16, 2025, to discuss innovations and seek partnerships.

QUANTRO Therapeutics achieved a breakthrough with its QUANTROseq platform, completing a 10-target multiplex-screening campaign. This innovation enables high-throughput screening of compound libraries, offering deep insights into transcriptional changes and on-target potency, advancing drug discovery for diseases like cancer and inflammation.

QUANTRO Therapeutics achieves a breakthrough in transcriptomic drug discovery with its first successful 10-target multiplex-screening, enhancing its QUANTROseq® platform's capability against diseases like cancer and inflammation. CEO Dr. Michael Bauer to present at Biotech Showcase and WuXi Global Forum in San Francisco, January 13-16, 2025.